​

Cytokinetics (CYTK) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CYTK Stock Forecast

Cytokinetics (CYTK) stock forecast, based on 34 Wall Street analysts, predicts a 12-month average price target of $92.27, with a high of $136.00 and a low of $69.00. This represents a 53.78% increase from the last price of $60.00.

$45 $64 $83 $102 $121 $140 High: $136 Avg: $92.27 Low: $69 Last Closed Price: $60

CYTK Stock Rating

Cytokinetics stock's rating consensus is Buy, based on 34 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 32 Buy (94.12%), 2 Hold (5.88%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 34 0 2 32 Strong Sell Sell Hold Buy Strong Buy

CYTK Price Target Upside V Benchmarks

TypeNameUpside
StockCytokinetics53.78%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts31521
Avg Price Target$84.67$90.67$85.95
Last Closing Price$60.00$60.00$60.00
Upside/Downside41.12%51.12%43.25%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 267103--20
Feb, 267103--20
Jan, 267103--20
Dec, 25794--20
Nov, 25884--20
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 10, 2026Roanna RuizRobert W. Baird$84.00$63.5532.18%40.00%
Mar 06, 2026Ashwani VermaUBS$69.00$60.5913.88%15.00%
Feb 20, 2026RBC Capital$101.00$68.1348.25%68.33%
Feb 03, 2026Srikripa DevarakondaTruist Financial$92.00$66.4738.41%53.33%
Jan 09, 2026Akash TewariJefferies$90.00$63.2442.31%50.00%
Jan 08, 2026Maxwell SkorMorgan Stanley$90.00$65.2537.93%50.00%
Dec 22, 2025Srikripa DevarakondaTruist Financial$84.00$67.3324.76%40.00%
Dec 22, 2025Morgan Stanley$71.00$67.395.36%18.33%
Dec 22, 2025Roanna RuizLeerink Partners$83.00$68.4621.24%38.33%
Dec 22, 2025RBC Capital$95.00$62.7251.47%58.33%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 10, 2026Leerink PartnersOutperformOutperformhold
Mar 06, 2026UBSNeutralNeutralhold
Feb 25, 2026Bank of America SecuritiesNeutralNeutralhold
Feb 20, 2026RBC CapitalOutperformOutperformhold
Jan 21, 2026B. RileyBuyBuyhold
Jan 09, 2026JefferiesBuyBuyhold
Dec 22, 2025Morgan StanleyOverweightOverweighthold
Dec 22, 2025RBC CapitalOutperformOutperformhold
Dec 22, 2025NeedhamBuyBuyhold
Dec 22, 2025Goldman SachsBuyBuyhold

Financial Forecast

EPS Forecast

$-20 $-13 $-6 $1 $8 $15 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.80$-4.33$-5.45$-5.26$-6.54---
Avg Forecast$-3.26$-4.06$-4.88$-5.24$-5.40$-4.04$-0.26$2.83
High Forecast$0.05$-0.19$-4.35$-4.55$-3.93$-2.50$0.30$11.50
Low Forecast$-14.80$-15.96$-5.34$-5.59$-6.97$-6.50$-1.29$-0.55
Surprise %-14.11%6.65%11.68%0.38%21.11%---

Revenue Forecast

$0 $900M $2B $3B $4B $5B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$70.43M$94.59M$7.53M$18.47M$88.04M---
Avg Forecast$20.72M$99.32M$21.85M$3.28M$47.78M$292.97M$720.92M$1.24B
High Forecast$77.12M$323.22M$91.92M$14.05M$169.91M$303.62M$757.84M$4.18B
Low Forecast$4.54M$26.48M$9.62M$279.05K$4.13M$282.31M$683.99M$101.57M
Surprise %239.94%-4.76%-65.53%463.28%84.25%---

Net Income Forecast

$-1B $-500M $0 $500M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-215.31M$-388.95M$-526.24M$-589.53M$-784.96M---
Avg Forecast$-181.31M$-178.74M$-526.24M$-489.37M$-632.39M$-497.99M$-47.73M$272.92M
High Forecast$-145.04M$-142.99M$-421.00M$-439.27M$-379.04M$-240.98M$29.04M$1.11B
Low Forecast$-217.57M$-214.49M$-631.49M$-539.46M$-672.43M$-627.51M$-124.50M$-52.90M
Surprise %18.76%117.61%-20.47%24.13%---

CYTK Forecast FAQ

Is Cytokinetics stock a buy?

Cytokinetics stock has a consensus rating of Buy, based on 34 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 32 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cytokinetics is a favorable investment for most analysts.

What is Cytokinetics's price target?

Cytokinetics's price target, set by 34 Wall Street analysts, averages $92.27 over the next 12 months. The price target range spans from $69 at the low end to $136 at the high end, suggesting a potential 53.78% change from the previous closing price of $60.

How does Cytokinetics stock forecast compare to its benchmarks?

Cytokinetics's stock forecast shows a 53.78% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Cytokinetics over the past three months?

  • March 2026: 35.00% Strong Buy, 50.00% Buy, 15.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 35.00% Strong Buy, 50.00% Buy, 15.00% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 35.00% Strong Buy, 50.00% Buy, 15.00% Hold, 0% Sell, 0% Strong Sell.

What is Cytokinetics’s EPS forecast?

Cytokinetics's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.04, marking a -38.23% decrease from the reported $-6.54 in 2025. Estimates for the following years are $-0.26 in 2027, and $2.83 in 2028.

What is Cytokinetics’s revenue forecast?

Cytokinetics's average annual revenue forecast for its fiscal year ending in December 2026 is $292.97M, reflecting a 232.77% increase from the reported $88.04M in 2025. The forecast for 2027 is $720.92M, and $1.24B for 2028.

What is Cytokinetics’s net income forecast?

Cytokinetics's net income forecast for the fiscal year ending in December 2026 stands at $-498M, representing a -36.56% decrease from the reported $-785M in 2025. Projections indicate $-47.73M in 2027, and $272.92M in 2028.